ASLN News and Press, ASLAN Pharmaceuticals Limited From 07/03/24

A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...

2024-07-02 09:02:05 ET ASLAN Pharmaceuticals Ltd (ASLN) announced stock split at a ratio of 1-for-8 on 2024-07-03 ... Full story available on KlickAnalytics.com

2024-06-28 15:00:00 ET More on the markets S&P 500: Stay Invested, But Pay Attention To These Risks SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation S&P 500 H1 performance: Market cap vs. Equal weight Biden-Trump pre...

2024-06-14 17:00:23 ET More on ASLAN Pharmaceuticals ASLAN Pharmaceuticals announces receipt of Nasdaq notice Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical earnings data for ASLAN Pharmaceuticals Financial information for ASLAN Pharm...

2024-06-12 16:41:08 ET More on ASLAN Pharmaceuticals ASLAN Pharmaceuticals announces receipt of Nasdaq notice Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical earnings data for ASLAN Pharmaceuticals Financial information for ASLAN Pharm...

Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and ...

2024-05-09 13:55:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ASLAN Pharma (NASDAQ: ASLN ) just reported results for the first quarter of 2024. ASLAN Pharma reported earnings per share of -53 cents. This was above the analyst estimat...

2024-05-09 08:03:11 ET More on ASLAN Pharmaceuticals ASLAN Pharmaceuticals announces receipt of Nasdaq notice ASLAN Pharmaceuticals announces $5M registered direct offering Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical earnings data ...

Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly ...

New positive data from an additional analysis of dupilumab -experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to...